SiliconBeat

Two years after naming Anthony Tebbutt its senior vice president for corporate strategy and business development, Alexza Pharmaceuticals has announced that his employment will end as of May 31.

Tebbutt, who worked for UCB, a Belgium pharmaceutical until October 2006, was paid $139,104  to cover certain expenses related to his relocation to the Bay Area when he was hired in March 2007. Since October 2007 he has been given a “monthly Read the rest of this entry »

Alexza Pharmaceuticals announced the elimination fo 52 employees, or a third of its staff, last week the same day it reported the cancellation with Endo Pharmaceticals of a joint development agreement for Alexza’s AZ-300 drug candidate designed to treat abnormal flare-ups of pain in addition to the chronic pain suffered by cancer patients and others.

Endo originally paid Alexza a $10 million Read the rest of this entry »

Alexza Pharmaceuticals announced positive results from its second Phase 3 clinical trial of its inhalation drug candidate, AZ-004, otherwise known as Staccato loxapine, being developed to treat acute agitation in patients with schizophrenia or bipolar disorder. The drug’s development is part of a partnership between Mountain View-based Alexza and Symphony Capital, a biotech-focused private equity firm.

Alexza reported that the trials showed that both the 5 mg and 10 mg doses showed Read the rest of this entry »